20 February 2024
20 February 2024
AstraZeneca will bolster its vaccine pipeline with a Phase III-ready candidate for respiratory infections.
The approval is based on findings from the ELEVATE UC Phase III programme, comprising the ELEVATE UC 52 and ELEVATE UC 12 trials.
An FDA approval in late 2024 would make it the first TROP2-directed therapy for non-small cell lung cancer (NSCLC) antibody drug conjugate patients.
The supplemental biologics licence application (sBLA) submission is based on findings from the ADHERE study, which assessed VYVGART Hytrulo in adults.
Applied plans to submit a new drug application following the announcement of positive interim data from its Phase III trial.
Biocytogen and Gilead are entering an antibody deal to leverage the discovery and development of new antibody therapeutics.
Novo Nordisk will receive upfront, milestone and royalty payments for developing and marketing the dermatology asset.
DEXTENZA offers dexamethasone to the ocular surface for up to 30 days without the use of preservatives.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
